FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308045507> ?p ?o ?g. }

• W4308045507 endingPage "765" @default.
• W4308045507 startingPage "756" @default.
• W4308045507 abstract "B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration-approved BCMA-directed CAR T products. However, despite high initial response rates, most patients eventually relapse. The outcomes of patients with disease recurrence after BCMA-directed CAR T have not been comprehensively studied, and such an analysis would help define optimal treatment strategies. We analyzed the salvage treatments and outcomes of 79 patients with multiple myeloma from two academic institutions, who had progression of disease after treatment with BCMA-directed CAR T. A total of 237 post-CAR T salvage treatment lines were used, and patients received a median of 2 (range, 1-10) treatment lines. The median overall survival from the date of relapse post-CAR T therapy was 17.9 months (95% confidence interval [CI], 14.0 non-estimable). The overall response rate to the first salvage regimen was 43.4%, with a median progression-free survival of 3.5 months (CI, 2.5-4.6). Thirty-five patients (44.3%) received a T-cell-engaging therapy (bispecific antibody or subsequent CAR T) as salvage treatment. The overall survival in patients who received subsequent T-cell-engaging therapy was not reached after a median follow up of 21.3 months. Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy. T-cell-engaging therapies appear to maintain pronounced clinical activity in this setting." @default.
• W4308045507 created "2022-11-07" @default.
• W4308045507 creator A5002010987 @default.
• W4308045507 creator A5002477157 @default.
• W4308045507 creator A5006108161 @default.
• W4308045507 creator A5009378735 @default.
• W4308045507 creator A5018841151 @default.
• W4308045507 creator A5021595775 @default.
• W4308045507 creator A5028046297 @default.
• W4308045507 creator A5030703994 @default.
• W4308045507 creator A5030726651 @default.
• W4308045507 creator A5032617342 @default.
• W4308045507 creator A5033256635 @default.
• W4308045507 creator A5038671529 @default.
• W4308045507 creator A5038880944 @default.
• W4308045507 creator A5043259076 @default.
• W4308045507 creator A5047805762 @default.
• W4308045507 creator A5054484092 @default.
• W4308045507 creator A5060701531 @default.
• W4308045507 creator A5068615370 @default.
• W4308045507 creator A5069157698 @default.
• W4308045507 creator A5070096873 @default.
• W4308045507 creator A5071374461 @default.
• W4308045507 creator A5074887540 @default.
• W4308045507 creator A5076589550 @default.
• W4308045507 date "2023-02-16" @default.
• W4308045507 modified "2023-10-14" @default.
• W4308045507 title "Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy" @default.
• W4308045507 cites W1971211622 @default.
• W4308045507 cites W2003734726 @default.
• W4308045507 cites W2115760271 @default.
• W4308045507 cites W2144728882 @default.
• W4308045507 cites W2146480092 @default.
• W4308045507 cites W2318069817 @default.
• W4308045507 cites W2486629951 @default.
• W4308045507 cites W2807637103 @default.
• W4308045507 cites W2901323206 @default.
• W4308045507 cites W2913073599 @default.
• W4308045507 cites W2921533600 @default.
• W4308045507 cites W2923396001 @default.
• W4308045507 cites W3131401867 @default.
• W4308045507 cites W3133229959 @default.
• W4308045507 cites W3176532045 @default.
• W4308045507 cites W3209765086 @default.
• W4308045507 cites W3215107644 @default.
• W4308045507 cites W3217436200 @default.
• W4308045507 cites W4200108738 @default.
• W4308045507 cites W4200308546 @default.
• W4308045507 cites W4224274398 @default.
• W4308045507 cites W4281714381 @default.
• W4308045507 cites W4281946301 @default.
• W4308045507 cites W4311449698 @default.
• W4308045507 cites W4381046716 @default.
• W4308045507 doi "https://doi.org/10.1182/blood.2022017848" @default.
• W4308045507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36327160" @default.
• W4308045507 hasPublicationYear "2023" @default.
• W4308045507 type Work @default.
• W4308045507 citedByCount "9" @default.
• W4308045507 countsByYear W43080455072023 @default.
• W4308045507 crossrefType "journal-article" @default.
• W4308045507 hasAuthorship W4308045507A5002010987 @default.
• W4308045507 hasAuthorship W4308045507A5002477157 @default.
• W4308045507 hasAuthorship W4308045507A5006108161 @default.
• W4308045507 hasAuthorship W4308045507A5009378735 @default.
• W4308045507 hasAuthorship W4308045507A5018841151 @default.
• W4308045507 hasAuthorship W4308045507A5021595775 @default.
• W4308045507 hasAuthorship W4308045507A5028046297 @default.
• W4308045507 hasAuthorship W4308045507A5030703994 @default.
• W4308045507 hasAuthorship W4308045507A5030726651 @default.
• W4308045507 hasAuthorship W4308045507A5032617342 @default.
• W4308045507 hasAuthorship W4308045507A5033256635 @default.
• W4308045507 hasAuthorship W4308045507A5038671529 @default.
• W4308045507 hasAuthorship W4308045507A5038880944 @default.
• W4308045507 hasAuthorship W4308045507A5043259076 @default.
• W4308045507 hasAuthorship W4308045507A5047805762 @default.
• W4308045507 hasAuthorship W4308045507A5054484092 @default.
• W4308045507 hasAuthorship W4308045507A5060701531 @default.
• W4308045507 hasAuthorship W4308045507A5068615370 @default.
• W4308045507 hasAuthorship W4308045507A5069157698 @default.
• W4308045507 hasAuthorship W4308045507A5070096873 @default.
• W4308045507 hasAuthorship W4308045507A5071374461 @default.
• W4308045507 hasAuthorship W4308045507A5074887540 @default.
• W4308045507 hasAuthorship W4308045507A5076589550 @default.
• W4308045507 hasBestOaLocation W43080455071 @default.
• W4308045507 hasConcept C121608353 @default.
• W4308045507 hasConcept C126322002 @default.
• W4308045507 hasConcept C141071460 @default.
• W4308045507 hasConcept C143998085 @default.
• W4308045507 hasConcept C2776364478 @default.
• W4308045507 hasConcept C2776694085 @default.
• W4308045507 hasConcept C2777701055 @default.
• W4308045507 hasConcept C2780775027 @default.
• W4308045507 hasConcept C2781413609 @default.
• W4308045507 hasConcept C2911194787 @default.
• W4308045507 hasConcept C3875195 @default.
• W4308045507 hasConcept C71924100 @default.
• W4308045507 hasConceptScore W4308045507C121608353 @default.
• W4308045507 hasConceptScore W4308045507C126322002 @default.

• next